Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Foot-and-Mouth Vaccine Signals Huge Advance in Global Disease Control

Published: Friday, March 29, 2013
Last Updated: Friday, March 29, 2013
Bookmark and Share
New FMDV vaccine designed to trigger optimum immune response.

Scientists have developed a new methodology to produce a vaccine for foot-and-mouth disease virus (FMDV). Because the vaccine is all synthetic, made up of tiny protein shells designed to trigger optimum immune response, it doesn’t rely on growing live infectious virus and is therefore much safer to produce.

Furthermore, these empty shells have been engineered to be more stable; making the vaccine much easier to store and reducing the need for a cold chain.

This is important research because it represents a big step forward in the global campaign to control FMDV in countries where the disease is endemic, and could significantly reduce the threat to countries currently free of the disease.

Crucially, this new approach to making and stabilizing vaccine could also impact on how viruses from the same family are fought, including polio.

This collaborative research was led by Professor David Stuart, Life Science Director at Diamond Light Source and MRC Professor of Structural Biology at the Department of Medicine University of Oxford and Dr Bryan Charleston, Head of Livestock Viral Diseases Programme at The Pirbright Institute.

Dr Bryan Charleston, whose team at The Pirbright Institute has developed a detailed understanding of the immune response to FMDV in cattle and is leading the vaccination trials work, says, “The FMDV epidemic in the UK in 2001 was disastrous and cost the economy billions of pounds in control measures and compensation. As a result of the outbreak the Royal Society recommended new approaches should be developed to control the virus should it happen again.

“This important work has been a direct result of the additional funding that was provided as a result of the 2001 outbreak to research this highly contagious disease. Using our detailed knowledge of the immune responses to FMDV in cattle we were able to define the characteristics that needed to be incorporated into the new vaccine platform to induce protection.”

Professor David Stuart, explains, “What we have achieved here is close to the holy grail of foot-and-mouth vaccines. Unlike the traditional vaccines, there is no chance that the empty shell vaccine could revert to an infectious form. This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to other viruses from the same family, such as poliovirus and hand foot and mouth disease, a human virus which is currently endemic in South-East Asia,”.

Key results were published in the journal PLOS Pathogens on Wednesday 27th March 2013. The work is principally funded by the Department for Environment, Food and Rural Affairs, UK (Defra) and the Wellcome Trust.

Clinical trials of the synthetic shell based vaccine on cattle carried out by Dr Charleston and his team have shown it is as effective as current vaccines. Whilst a commercial product is still several years away the team hopes that the technology can be transferred as quickly as possible to make it available to a global market.

Professor Stuart says; “Instead of using infectious virus as the basis for the vaccine, which is the main traditional method of vaccine development, the team using a methodology developed by Professor Ian Jones from the University of Reading synthetically created empty protein shells to imitate the protein coat that forms the strong outer layer of the virus. By using Diamond’s visualization capabilities and the expertise of Oxford University in structural analysis and computer simulation, we were able to visualize something a billion times smaller than a pinhead and further enhance the design atom by atom of the empty shells. Through information gained at Diamond, we also verified that these have essentially the same structure as the native virus to ensure an appropriate immune response.”

Fine adjustments have been made to the empty shell to improve stability to produce a vaccine that is inherently more stable than live virus based products. This makes transporting and storing the vaccine much easier, as the pre-clinical trials have shown it to be stable at temperatures up to 56°C for at least two hours.

The disease is endemic in central Africa and some parts of the Middle East and Asia (ref. World map), so this is a major advantage over the traditional vaccine, which has to be produced and stored in a chilled and stable environment.

Dr Charleston adds, “The ability to produce a vaccine outside of high containment and that does not require a cold storage chain should greatly increase production capacity and reduce costs. Globally there is an undersupply of the vaccine due to the high cost of production and this new development could solve this problem and significantly control foot-and-mouth disease worldwide.

“Furthermore, the complete absence of some viral proteins from this new vaccine will also allow companion diagnostic tests to be further refined to demonstrate the absence of infection in vaccinated animals with greater confidence.”

Professor Stuart, concludes, “Foot-and-mouth disease is one of the most economically important diseases in livestock worldwide. With approximately 3 to 4 billion doses of vaccine administered every year, you can start appreciating the pertinence of our work. What we achieved is down to the continued support of our many funding agencies, the individual and collective perseverance of the entire collaboration and access to 21st century scientific tools to push the boundaries of scientific research.”

Nigel Gibbens, the UK’s Chief Veterinary Officer comments on the work, “This vaccine is a major breakthrough that has the potential to be an invaluable new weapon in the fight to eradicate foot-and-mouth disease. There are many more years of work and research to be done to get this vaccine ready for use, but this is undoubtedly an exciting leap forward. Once available, vaccines of this type would have clear advantages over current technology as a possible option to help control the disease should we ever have another FMD outbreak.

“This vaccine has been developed using some truly groundbreaking techniques which are a credit to the quality of British scientists working in the field of animal health.”

Development of the vaccine was supported by a Translation Award from the Wellcome Trust. Richard Seabrook, Head of Business Development at the Wellcome Trust, said: “Most people in the UK will remember the foot-and-mouth outbreaks of the 1960s and early 2000s, but FMD is a daily scourge for millions living in countries where the disease is endemic. An affordable vaccine is urgently needed to alleviate the huge economic burden that the disease places on the farming industry, particularly in the developing world. This vaccine still has some way to go before it will be available to farmers but these early results are very encouraging.”

Dr Charleston concludes, “We hope that a broad range of research groups working on vaccine development for viruses related to foot-and-mouth disease will be interested in taking our discovery forward to help tackle other major global disease challenges.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Research will Show How the Environment Could Change the Way We Eat
A new study funded by the Wellcome Trust will investigate how environmental changes over the next 20-30 years may impact the way we eat, in the UK and worldwide.
Thursday, July 16, 2015
Single Cells Seen In Unprecedented Detail
Parallel sequencing of DNA and RNA provides insight into secret world of cells.
Wednesday, April 29, 2015
The First Fine-Scale Genetic Map Of The British Isles
Many people in the UK feel a strong sense of regional identity, and it now appears that there may be a scientific basis to this feeling, according to a landmark new study into the genetic makeup of the British Isles.
Thursday, March 19, 2015
Project to Focus on Link Between Immune System and Brain Disorders
Researchers to investigate whether mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer’s, could be treated by targeting the immune system.
Monday, December 22, 2014
Ability Of HIV To Cause AIDS Could Be Slowing
Research indicates that HIV is becoming less virulent.
Tuesday, December 02, 2014
£5m Programme to Investigate Brain Networks
The studies in primates will look at how networks of millions of neurons in the brain give rise to key functions.
Friday, May 16, 2014
Lonely Bacteria are More Likely to Become Antibiotic-resistant
Scientists from the University of Manchester have discovered that microbes in smaller groups are more likely to mutate, resulting in higher rates of antibiotic resistance.
Wednesday, April 30, 2014
Faster Visa Endorsement will Support International Mobility for Top Researchers
This visa route is designed for the brightest and best bringing them from outside the European Economic Area to the UK.
Monday, April 07, 2014
Stem Cell Transplant Repairs Damaged Gut in Mouse Model of IBD
The findings pave the way for patient-specific regenerative therapies for inflammatory bowel diseases such as ulcerative colitis.
Friday, October 18, 2013
Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate Published
Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.
Monday, February 04, 2013
Discovery of Molecular Pathway of Alzheimer's Disease Reveals New Drug Targets
The study gives the most detailed understanding yet of the complex processes leading to Alzheimer's.
Wednesday, November 21, 2012
Wellcome Trust and MRC Invest £13m to Create a New National Stem Cell Resource
The Wellcome Trust and Medical Research Council today announced a £12.75 million initiative to create a catalogue of high-quality adult stem cells (iPS cells).
Wednesday, November 07, 2012
Study Reveals Extent of Type 2 Diabetes Problem in Black and Minority Ethnic Populations
According to the study half of all people of South Asian, African and African-Caribbean descent will develop diabetes by age 80.
Friday, September 14, 2012
£30 Million Boost for Biomedical Engineering Research
Partnership will provide funding for long-term projects that address healthcare needs.
Wednesday, September 12, 2012
Wellcome Trust and MRC Invest in World-Class Stem Cell Institute
Two of the UK’s largest funders of medical research are to invest £8 million in a new world-leading centre for stem cell biology and medicine.
Thursday, August 09, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!